Claims for Patent: 6,133,310
✉ Email this page to a colleague
Summary for Patent: 6,133,310
| Title: | Method of treatment of rosacea |
| Abstract: | A method of treatment of acne rosacea consists of the application, in the form of either a lotion or a cream, constituting a mixture of a therapeutically effective amount of invermectin in water, in the case of the lotion, and invermectin and a pharmaceutically acceptable carrier, in the case of the cream. Application to the affected area occurs daily for a period of one week and, thereafter, two to four times per month for a period of up to one year. |
| Inventor(s): | Parks; L. Dean (Ocala, FL) |
| Assignee: | |
| Application Number: | 09/383,594 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,133,310 |
| Patent Claims: |
1. A method of treatment of acne rosacea,
consisting of the steps of:
(a) mixing a therapeutically effective amount of invermectin with water to thereby form a lotion; (b) applying said lotion daily to an affected area for a period of about seven days; and (c) repeating such application two to four times a month for a period of several months; and, optionally, repeating application of said lotion about once a month thereafter. 2. The method as recited in claim 1, in which said therapeutically effective amount of invemectin comprises a concentration of at least 750 mcg/ml. 3. A method of treatment of rosacea, consisting of the steps of: (a) mixing a therapeutically effective amount of invermectin with a pharmaceutically acceptable carrier to thereby form a cream; applying said cream daily to an affected area for a period of about seven days; and (b) repeating such application two to four times a month for a period of several months; and, optionally, repeating application of said cream about once a month thereafter. 4. The method as recited in claim 3 in which said therapeutically effective amount of invermectin comprise a concentration of at least 750 mcg/cc within said cream. 5. The method as recited in claim 4 in which said pharmaceutically acceptable carrier is selected from the group of carriers consisting of propylene glycol, sodium lauryl sulfate, xanthum gum, or combinations thereof. |
